Erratum: Effects of telmisartan on the cerebral circulation of hypertensive patients with chronic-stage stroke (Hypertension Research (2012) 35 (1171-1175) DOI: 10.1038/hr.2012.105);Effects of telmisartan on the cerebral circulation of hypertensive patients with chronic-stage stroke

Hypertension Research

Volumn 35, Issue 12, 2012, Pages 1171-1175

  Deguchi, Ichiro ^a   Furuya, Daisuke ^a   Fukuoka, Takuya ^a   Tanahashi, Norio ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

cerebral blood flow; chronic stage stroke; peroxisome proliferator activated receptor gamma (PPARg) agonist; telmisartan

Indexed keywords

CYSTEINE ETHYL ESTER TC 99M; TELMISARTAN;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; BRAIN BLOOD FLOW; BRAIN CIRCULATION; BRAIN DAMAGE; CENTRAL SULCUS; CEREBROVASCULAR ACCIDENT; CHRONIC DISEASE; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; FEMALE; HEMISPHERE; HIPPOCAMPUS; HUMAN; HYPERTENSION; LACUNAR STROKE; MALE; PARIETAL CORTEX; POSTERIOR FOSSA; PRECENTRAL SULCUS; PROSPECTIVE STUDY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTOLIC BLOOD PRESSURE; TEMPORAL CORTEX; THALAMUS VENTRAL NUCLEUS;

EID: 84870770075     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2012.139     Document Type: Erratum

References (27)

1. Kannel WB, Wolf PA, McGee DL, Dawber TR, McNamara P, Castelli WP. Systolic bloodpressure, arterial rigidity, and risk of stroke. The Framingham Study. JAMA 1981; 245:1225-1229.
2. Shinohara Y, Ogawa A, Suzuki N, Katayama Y, Kimura A. Japanese Guidelines for theManagement of Stroke-the Joint Committee on Guidelines for the Management ofStroke. Kyowa Kikaku: Tokyo, 2009, pp 85-86.
3. Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W,Dominiak P, Diener HC, MOSES Study Group. Morbidity and mortality after stroke,eprosartan compared with nitrendipine for secondary prevention: principal results of aprospective randomized controlled study (MOSES). Stroke 2005; 36: 1218-1226.
4. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH,Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J,Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C,Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T,Weber M, Yoon BW. PRoFESS Study Group. Telmisartan to prevent recurrent stroke andcardiovascular events. N Engl J Med 2008; 359: 1225-1237.
5. Schrader J,Lüders S, Kulschewski A, Berger J, Zidek W, Treib J, Einhäupl K, DienerHC, Dominiak P. Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group.The ACCESS Study: evaluation of acute candesartan cilexetil therapy in strokesurvivors. Stroke 2003; 34: 1699-1703.
6. Hong KS, Kang DW, Bae HJ, Kim YK, Han MK, Park JM, Rha JH, Lee YS, Koo JS, ChoYJ, Kwon SU, Kim SE, Park SH. Effect of cilnidipine vs losartan on cerebral blood flowin hypertensive patients with a history of ischemic stroke: a randomized controlled trial.Acta Neurol Scand 2010; 121: 51-57.
7. Moriwaki H, Uno H, Nagakane Y, Hayashida K, Miyashita K, Naritomi H. Losartan, anangiotensin II (AT1) receptor antagonist, preserves cerebral blood flow in hypertensivepatients with a history of stroke. J Hum Hypertens 2004; 18: 693-699.
8. Kimura Y, Kitagawa K, Oku N, Kajimoto K, Kato H, Tanaka M, Sakaguchi M, HougakuH, Sakoda S, Hatazawa J. Blood pressure lowering with valsartan is associated withmaintenance of cerebral blood flow and cerebral perfusion reserve in hypertensivepatients with cerebral small vessel disease. J Stroke Cerebrovasc Dis 2010; 19:85-91.
9. Matsumoto S, Shimodozono M, Miyata R, Kawahira K. Benefits of the angiotensin IIreceptor antagonist olmesartan in controlling hypertension and cerebral hemodynamicsafter stroke. Hypertens Res 2009; 32: 1015-1021.
10. Haraguchi T, Takasaki K, Naito T, Hayakawa K, Katsurabayashi S, Mishima K, IwasakiK, Fujiwara M. Cerebroprotective action of telmisartan by inhibition of macrophages/microglia expressing HMGB1 via a peroxisome proliferator- activated receptor gammadependentmechanism. Neurosci Lett 2009; 464: 151-155.
11. Iwanami J, Mogi M, Tsukuda K, Min LJ, Sakata A, Jing F, Iwai M, Horiuchi M. Lowdose of telmisartan prevents ischemic brain damage with peroxisome proliferatoractivatedreceptor-gamma activation in diabetic mice. J Hypertens 2010; 28:1730-1737.
12. Kasahara Y, Taguchi A, Uno H, Nakano A, Nakagomi T, Hirose H, Stern DM, Matsuyama T.Telmisartan suppresses cerebral injury in a murine model of transient focal ischemia.Brain Res 2010; 1340: 70-80.
13. Dupuis F, Vincent JM, Limiñana P, Chillon JM, Capdeville-Atkinson C, Atkinson J.Effects of suboptimal doses of the AT1 receptor blocker, telmisartan, with theangiotensin-converting enzyme inhibitor, ramipril, on cerebral arterioles in spontaneouslyhypertensive rat. J Hypertens 2010; 28: 1566-1573.
14. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptorblockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation2004; 109: 2054-2057.
15. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J,Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptorantagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43:993-1002.
16. Nishimura Y, Ito T, Saavedra JM., Angiotensin II AT. Angiotensin II AT (1) blockadenormalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneouslyhypertensive rats. Stroke 2000; 31: 2478-2486.
17. Takada J, Ibayashi S, Ooboshi H, Ago T, Ishikawa E, Kamouchi M, Kitazono T, Iida M.Valsartan improves the lower limit of cerebral autoregulation in rats. Hypertens Res2006; 29: 621-626.
18. Dupuis F, Atkinson J, Limiñana P, Chillon JM. Comparative effects of the angiotensin IIreceptor blocker, telmisartan, and the angiotensin- converting enzyme inhibitor,ramipril, on cerebrovascular structure in spontaneously hypertensive rats. J Hypertens2005; 23: 1061-1066.
19. Kumai Y, Ooboshi H, Ago T, Ishikawa E, Takada J, Kamouchi M, Kitazono T, Ibayashi S,Iida M. Protective effects of angiotensin II type 1 receptor blocker on cerebralcirculation independent of blood pressure. Exp Neurol 2008; 210: 441-448.
20. Saavedra JM, Benicky J, Zhou J. Mechanisms of the anti-ischemic effect ofangiotensin II AT(1) receptor antagonists in the brain. Cell Mol Neurobiol 2006; 26:1099-1111.
21. Nagata R, Kawabe K, Olmesartan Ikeda K. An angiotensin II receptor blocker, restorescerebral hypoperfusion in elderly patients with hypertension. J Stroke Cerebrovasc Dis2010; 19: 236-240.
22. Tsukuda K, Mogi M, Iwanami J, Min LJ, Sakata A, Jing F, Iwai M, Horiuchi M. Cognitivedeficit in amyloid-beta-injected mice was improved by pretreatment with a low dose oftelmisartan partly because of peroxisome proliferator- activated receptor-gamma activation.Hypertension 2009; 54: 782-787.
23. Park JS, Cho MH, Lee KY, Kim CS, Kim HJ, Nam JS, Ahn CW, Cha BS, Lim SK,Kim KR, Lee HC. The effects of pioglitazone on cerebrovascular resistance in patientswith type 2 diabetes mellitus. Metabolism 2007; 56: 1081-1086.
24. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. Efficacy of PPAR-g agonistpioglitazone in mild Alzheimer disease. Neurobiol Aging 2011; 32: 1626-1633.
25. Mogi M, Horiuchi M. Effects of angiotensin II receptor blockers on dementia.Hypertens Res 2009; 32: 738-740.
26. Kume K, Hanyu H, Sakurai H, Takada Y, Onuma T, Iwamoto T. Effects of telmisartan oncognition and regional cerebral blood flow in hypertensive patients with Alzheimer'sdisease. Geriatr Gerontol Int 2011; 12: 207-214.
27. Imabayashi E, Matsuda H, Yoshimaru K, Kuji I, Seto A, Shimano Y, Ito K, Kikuta D,Shimazu T, Araki N. Pilot data on telmisartan short-term effects on glucose metabolismin the olfactory tract in Alzheimer's disease. Brain and Behavior 2011; 1: 63-69.